Key result
Teriflunomide treatment reduced EBV and HHV-6 antibody titers at 6 months, and higher baseline EBNA-1 IgG titers and older age were associated with a higher probability of achieving no evidence of disease activity at 24 months.
Why the study?
EBV and HHV-6 are associated with multiple sclerosis, and preclinical data showed teriflunomide promotes viral clearance and inhibits lytic EBV infection in vitro.
Does teriflunomide reduce humoral response against EBV and HHV-6 in patients with multiple sclerosis?
Cohort (n=101)
Yes
Does teriflunomide reduce humoral response against EBV and HHV-6 in patients with multiple sclerosis?
Teriflunomide treatment in MS patients is associated with reduced IgG antibody titers against EBV and HHV-6, and higher baseline EBNA-1 IgG titers predict better clinical response.
Answers are grounded in this paper and cite their sources.
Teriflunomide-associated EBV/HHV-6 titer reductions in MS warrant monitoring; observational data leave open antiviral contribution to NEDA-3.
Background Epstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6) have been associated with multiple sclerosis (MS). Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing forms of MS. In the preclinical Theiler’s murine encephalitis virus model of MS, the drug demonstrated an increased rate of viral clearance versus the vehicle placebo. Furthermore, teriflunomide inhibits lytic EBV infection in vitro. Objective 1. To evaluate the humoral response against EBV and HHV-6 prior to teriflunomide treatment and 6 months later. 2. To correlate the variation in the humoral response against EBV and HHV-6 with the clinical and radiological response after 24 months of treatment with teriflunomide. 3. To analyze the utility of different demographic, clinical, radiological, and environmental data to identify early biomarkers of response to teriflunomide. Methods A total of 101 MS patients (62 women; mean age: 43.4 years) with one serum prior to teriflunomide onset and another serum sample 6 months later were recruited. A total of 80 had been treated for at least 24 months, 13 had stopped teriflunomide before 24 months, and 8 were currently under teriflunomide therapy but with less than 24 months of follow-up. We analyzed the levels of the viral antibodies titers abovementioned in serum samples with ELISA commercial kits, and the levels of serum neurofilament light chain (Nf-L). Results Antiviral antibody titers decreased for EBNA-1 IgG (74.3%), VCA IgG (69%), HHV-6 IgG (60.4%), and HHV-6 IgM (73.3%) after 6 months of teriflunomide. VCA IgG titers at baseline correlated with Nf-L levels measured at the same time (r = 0.221; p = 0.028) and 6 months later (r = 0.240; p = 0.017). We found that higher EBNA-1 titers (p = 0.001) and a higher age (p = 0.04) at baseline were associated with NEDA-3 conditions. Thus, 77.8% of patients with EBNA-1 >23.0 AU and >42.8 years (P50 values) were NEDA-3. Conclusion Treatment with teriflunomide was associated with a reduction of the levels of IgG antibody titers against EBV and HHV-6. Furthermore, higher EBNA-1 IgG titers prior to teriflunomide initiation were associated with a better clinical response.
No takes yet. Share an insight, caveat, or question.
Domínguez‐Mozo et al. (2023) conducted a cohort in Relapsing-remitting multiple sclerosis (n=101). Teriflunomide vs. Baseline / Low EBNA-1 and age was evaluated on NEDA-3 (no evidence of disease activity) at 24 months for patients with baseline EBNA-1 ≥23.0 AU and age ≥42.8 years vs those below median values (OR 5.8, p=0.01). Teriflunomide treatment reduced EBV and HHV-6 antibody titers at 6 months, and higher baseline EBNA-1 IgG titers and older age were associated with a higher probability of achieving no evidence of disease activity at 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: